Sage Journals: Discover world-class research

Retricted access

Research article

First published 1992-1

A Survey of Therapeutic Substitution Programs in Ten Boston Area Hospitals

Sheila R. Shulman, Patricia A. Dicerbo, Marianne E. Ulcickas [...]

Therapeutic Innovation & Regulatory Science

Retricted access

Case report

First published 1988-2

Therapeutic Substitution in the Health Maintenance Organization Outpatient Environment

Paul L. Doering, Wayne L. Russell, William C. McCormick [...]

Annals of Pharmacotherapy

Retricted access

Other

First published 1989-1

Clinical Differences among Nonsteroidal Antiinflammatory Drugs: Implications for Therapeutic Substitution in Ambulatory Patients

Richard A. Levy, Dorothy L. Smith

Annals of Pharmacotherapy

Retricted access

Research article

First published 2011-4

Economic Impact of Therapeutic Substitution of a Brand Selective Serotonin Reuptake Inhibitor with an Alternative Generic Selective Serotonin Reuptake Inhibitor in Patients with Major Depressive Disorder

Eric Q Wu, Andrew P Yu, Veronique Lauzon [...]

Annals of Pharmacotherapy

Retricted access

Research article

First published 2008-05

Comparison of Therapeutic Antibiotic Treatments on Tissue-Engineered Human Skin Substitutes

Angela L. Gibson, Michael J. Schurr, Sandy J. Schlosser [...]

Tissue Engineering Part A: Research Advances

Retricted access

Research article

First published 2017-10

Impact of Inpatient Automatic Therapeutic Substitutions on Postdischarge Medication Prescribing

Pooja J. Shah, Jennifer L. Cruz, Ashley L. Pappas [...]

Hospital Pharmacy

Retricted access

Research article

First published 1995-3

Automatic therapeutic substitution: cost savings with intravenous push famotidine

Susan J. Markowsky, Maria L. Santbiro

Annals of Pharmacotherapy

Retricted access

Research article

First published 2007

Substituted Organosiloxanes as Potential Therapeutics for Treatment and Prevention of Neurodegenerative Diseases

Orrie M. Friedman, Paul Matsudaira, Arthur H. Reis [...]

Journal of Alzheimer’s Disease

Retricted access

Research article

First published 2019

Analysis of the Authorized Target Populations for Fixed Dose Combination Products Between 2000 and 2017 Reveals Discrepancies Between EMA’s and FDA’s Views on Initial Dual-Therapy

Ole Jannik Bjerrum, Sascha Eichendorff, Nada Bassam Alkis

Therapeutic Innovation & Regulatory Science

Retricted access

Research article

First published 2015-5

The Effects of State Pharmacy Drug Product Selection Laws on Statin Patient Generic-To-Branded Drug Switch-Backs

George A. Chressanthis, Nayla G. Dahan, Kevin J. Fandl

The American Economist

Search results